BTC
Showing 1 - 25 of 240
Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct Trial run by the National Cancer Institute (NCI) (oxaliplatin,
Not yet recruiting
- Biliary Cancer
- +2 more
- oxaliplatin
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
May 13, 2023
Biliary Tract Tumors Trial (Total Neoadjuvant Treatment)
Not yet recruiting
- Biliary Tract Neoplasms
- Total Neoadjuvant Treatment
- (no location specified)
Sep 7, 2023
Chronic Constipation Trial in Wonju (Electrolyzed Alkaline Ionizer)
Completed
- Chronic Constipation
- Electrolyzed Alkaline Ionizer
-
Wonju, Ganwon-do, Korea, Republic ofWonju College of Medicine
Feb 8, 2023
Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance Study -
Not yet recruiting
- Biliary Tract Cancer
- (no location specified)
Apr 26, 2023
Biliary Tract Cancer, Immune Checkpoint Inhibitor, Predictive Cancer Model Trial in Beijing (Immune Checkpoint Inhibitors)
Recruiting
- Biliary Tract Cancer
- +2 more
- Immune Checkpoint Inhibitors
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical Colle
Oct 5, 2023
Biliary Tract Carcinoma Trial in Beijing (Gemcitabine, S1, Tislelizumab)
Not yet recruiting
- Biliary Tract Carcinoma
- Gemcitabine
- +2 more
-
Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical Colle
Apr 10, 2023
Biliary Tract Cancer, Cholangiocarcinoma Trial in Italy (Gemcitabine, Nab paclitaxel, Cisplatin)
Not yet recruiting
- Biliary Tract Cancer
- Cholangiocarcinoma
- Gemcitabine
- +4 more
-
Ancona, Italy
- +18 more
Sep 16, 2023
Incidental Gallbladder Carcinoma-Permanent Platform Including
Recruiting
- Biliary Tract Cancer
- Neoadjuvant, Adjuvant and 1st Line
-
Frankfurt, GermanyKrankenhaus Nordwest GmbH
Aug 3, 2022
Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer Trial in Madison (Gemcitabine, Cisplatin, Zimberelimab)
Not yet recruiting
- Biliary Tract Carcinoma
- +2 more
- Gemcitabine
- +3 more
-
Madison, WisconsinUniversity of Wisconsin
Sep 15, 2023
Advanced Biliary Tract Cancer Trial in Changsha (IBI310, sintilimab)
Not yet recruiting
- Advanced Biliary Tract Cancer
-
Changsha, Hunan, ChinaHunan cancer Hospital
Dec 13, 2022
Intrahepatic Cholangiocarcinoma Trial in Shanghai (GP+PD-1+Tight)
Withdrawn
- Intrahepatic Cholangiocarcinoma
-
Shanghai, Shanghai, ChinaZhongshan hospital, Fudan University
Mar 22, 2022
Incidental Gallbladder Carcinoma, Biliary Tract Cancer Trial in Frankfurt (Gemcitabine, Cisplatin, Oncologically radical
Recruiting
- Incidental Gallbladder Carcinoma
- Biliary Tract Cancer
- Gemcitabine
- +3 more
-
Frankfurt, GermanyKrankenhaus Nordwest gGmbH
Sep 7, 2022
Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma Trial in Zhengzhou, Nanjing (SHR-1210, Apatinib, FOLFOX4)
Active, not recruiting
- Advanced Primary Liver Cancer
- Advanced Biliary Tract Carcinoma
- SHR-1210
- +3 more
-
Zhengzhou, Henan, China
- +1 more
Apr 26, 2022
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary
Recruiting
- Biliary Tract Cancer
- Blood drawing
-
Guangzhou, Guangdong, China
- +1 more
Dec 28, 2022
Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer Trial in Guangzhou (Camrelizumab and Apatinib Plus GP)
Not yet recruiting
- Locally Advanced Biliary Tract Cancer
- Metastatic Biliary Tract Cancer
- Camrelizumab and Apatinib Plus GP
-
Guangzhou, Guangdong, ChinaCancer center of SunYat-sen University
Feb 15, 2023
Advanced Biliary Tract Cancer Trial in Guangzhou (Envofolimab, Lenvatinib, Gemcitabine)
Recruiting
- Advanced Biliary Tract Cancer
- Envofolimab
- +3 more
-
Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Sun Yat-sen University
Oct 11, 2022
Intrahepatic Cholangiocarcinoma Trial in Germany (Durvalumab, Tremelimumab)
Recruiting
- Intrahepatic Cholangiocarcinoma
-
Dresden, Germany
- +7 more
Apr 13, 2022
Biliary Tract Tumors, Liver Cancer, Hepatocellular Carcinoma Trial run by the NCI (Durvalumab, Tremelimumab, Trans-arterial
Active, not recruiting
- Biliary Tract Neoplasms
- +4 more
- Durvalumab
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Mar 1, 2022
Biliary Tract Cancer Trial in Seoul (Pemetrexed 500 MG, Erlotinib)
Recruiting
- Biliary Tract Cancer
- Pemetrexed 500 MG
- Erlotinib
-
Seoul, Korea, Republic of
- +1 more
Jun 13, 2022
Biliary Tract Adenocarcinoma Trial in Shanghai (HAIC, Gemcitabine, Oxaliplatin)
Enrolling by invitation
- Biliary Tract Adenocarcinoma
- HAIC
- +4 more
-
Shanghai, ChinaFudan University Shanghai Cancer Center
May 27, 2022
Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial run by the NCI (durvalumab,
Recruiting
- Hepatocellular Cancer
- +2 more
- durvalumab
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Biliary Tract Cancer Trial in Shanghai (Capecitabine combined with lenvatinib and tislelizumab)
Recruiting
- Biliary Tract Cancer
- Capecitabine combined with lenvatinib and tislelizumab
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 23, 2022
Biliary Tract Tumors, Cholangiocarcinoma, Bile Duct Cancer Trial run by the NCI (Pembrolizumab (MK-3475), Oxaliplatin,
Completed
- Biliary Tract Neoplasms
- +4 more
- Pembrolizumab (MK-3475)
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Dec 1, 2021